Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.
about
From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumorsSystematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumoursFavourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursPhase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours.Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature.Initial study of radiological and clinical efficacy radioembolization using 188Re-human serum albumin (HSA) microspheres in patients with progressive, unresectable primary or secondary liver cancers.Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)A multimodal approach to the management of neuroendocrine tumour liver metastasesStroma targeting nuclear imaging and radiopharmaceuticals.Emerging approaches in the management of patients with neuroendocrine liver metastasis: role of liver-directed and systemic therapies.Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicityPancreatic neuroendocrine tumors: approach to treatment with focus on sunitinibDisseminated Pancreatic Neuroendocrine Neoplasm (NEN) with an Uncommon Localisation in the Central Nervous System. A Case ReportRole of everolimus in pancreatic neuroendocrine tumors.Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors.Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.Yttrium-labelled peptides for therapy of NET.Quality of clinical trials in gastroenteropancreatic neuroendocrine tumours.Radionuclide therapy via SSTR: future aspects from experimental animal studies.Treatment of liver metastases in patients with digestive neuroendocrine tumors.The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.Role of surgery and transplantation in the treatment of hepatic metastases from neuroendocrine tumor.Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.In vivo evaluation of PEGylated ⁶⁴Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT.Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.The safety of available treatments options for neuroendocrine tumors.Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.Neuroendocrine tumors: a focus on liver metastatic lesions.Theranostics in nuclear medicine practiceSomatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity.Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate.The difference between medicine and magic is that magicians know what they are doingENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
P2860
Q26822011-DACFC9EB-78F5-45D4-8BA0-6D751FF4E6B1Q28071978-3497E9C6-86E3-4C12-B49C-507320CF8E36Q28247667-841E2BA5-D146-49B1-99FE-358661E54463Q33392694-6FD3653A-CAE1-4A12-8842-2ACE99C72C21Q33435622-B9069D55-9559-4E31-8EAD-61624F9CE734Q33700134-7BFC99B6-2EC5-43F1-99A9-3B8A17B1CE1DQ33737587-D5F37D3F-AB3B-470B-A826-3C2033A76663Q34062165-BC72C793-4ED8-40BA-917B-72E9394970E0Q35738251-1D4A13FD-15C2-43C4-90A6-9B8ABBCD040DQ35760798-B41ADE42-02BB-4654-B883-D476FF3BDC3DQ35810562-24FA6B06-C74A-4006-A437-6B5A0CAEDDCDQ35999606-F8C16335-22AF-4FF1-A4C1-3CE429BF90F2Q36512778-1EF50233-2ED8-4E10-A2FB-58AD8D95284EQ36775316-F8CB3BC3-2677-4372-B48C-4C10EE1ED27FQ37130616-3FDB4045-2D9A-4585-94A6-AE21AE678A99Q37691470-76B2C7C0-4A8F-40F4-A9C3-91780BF074A2Q37935772-19E3EBA8-DEA3-4965-A9C6-E530AA7DBF62Q37936908-ABFBBC79-136D-4F18-BF59-86B622060DF4Q37975101-20E9F04C-6307-4B9D-9E0F-D10235BB5696Q37990401-D17CE414-13BF-4460-9A8A-D9F6C39F60F2Q37993338-ACB98438-A63A-4F1D-9633-ADC04FA1845DQ38008839-672C7BF0-5D1A-4DBE-8999-434577FBD5C9Q38029275-6718DFFE-D531-4470-8914-9EEEE63F768CQ38219225-9D66C035-A303-47D4-9BA8-FD9D2FA5C4B1Q38262113-4A398A05-CA48-4855-99A4-1EB843D3CCF2Q38769465-6EB5F1CE-2365-4EFE-A0F4-47C178E10190Q38813559-3FF42B2F-0A1F-4149-B4DA-6E94F805A78BQ38870046-F704CDB2-F222-4C37-85A6-69E5E3ABE2F3Q38909078-9B344BF5-D5A4-4796-BF83-49905D12C8C2Q39433254-1554E725-56B3-4F17-B9E5-8845D4854558Q41244010-9D0AAC7C-2C78-43C9-BDC4-9B6B875A922DQ42175071-AAD86DBE-7F6C-47FB-89B2-64EB08178D70Q42373162-EE494A89-A203-474E-AEED-8F969CC2306EQ42548064-4629CFF3-C25C-43E6-AA58-59C8636D1DB2Q44670305-01DF7BE5-D260-4785-8BB8-75516AF2BD0DQ48136353-1788410C-5E12-462B-9759-C65FD27F3125Q52677878-2AF796A8-C08E-40A7-886D-21AA71E88BCEQ54652791-A32D354E-FF61-4551-BB03-93E7CC3B2C83Q57758762-09EC3E80-CCC7-4BB9-A07E-55D46FCCBF52Q57990732-0452E6BC-AF3D-4D09-9B92-FDD8DB9C39BD
P2860
Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Efficacy of radionuclide treat ...... (GEP-NETs): a phase II study.
@en
Efficacy of radionuclide treat ...... atic neuroendocrine carcinomas
@nl
type
label
Efficacy of radionuclide treat ...... (GEP-NETs): a phase II study.
@en
Efficacy of radionuclide treat ...... atic neuroendocrine carcinomas
@nl
prefLabel
Efficacy of radionuclide treat ...... (GEP-NETs): a phase II study.
@en
Efficacy of radionuclide treat ...... atic neuroendocrine carcinomas
@nl
P2093
P2860
P356
P1433
P1476
Efficacy of radionuclide treat ...... s (GEP-NETs): a phase II study
@en
P2093
A Nasierowska-Guttmejer
A Sankowski
J R Buscombe
N Seklecka
R Mikolajczak
P2860
P304
P356
10.1093/ANNONC/MDP372
P577
2009-10-15T00:00:00Z